Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | GNPAT | O15228 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 3/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026003 | 1.00 | FOLH1 (0.49) | FOLH1GNPATSMN1; SMN2KDM4EMAPT | |
| SCHEMBL30526285 | 1.00 | FOLH1 (0.49) | FOLH1GNPATSMN1; SMN2KDM4EMAPT | |
| SCHEMBL468901 | 1.00 | FOLH1 (0.49) | FOLH1GNPATSMN1; SMN2KDM4EMAPT | |
| Acetic Acid SCHEMBL28406175 | 0.98 | FOLH1 (0.48) | FOLH1GNPATSMN1; SMN2KDM4EMAPT | |
| SCHEMBL9438405 | 0.98 | FOLH1 (0.48) | FOLH1GNPATSMN1; SMN2KDM4EMAPT | |
| Water SCHEMBL29401510 | 0.98 | FOLH1 (0.48) | FOLH1GNPATSMN1; SMN2KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL4422480 | 0.98 | FOLH1 (0.48) | FOLH1GNPATSMN1; SMN2KDM4EMAPT | |
| SCHEMBL468736 | 0.95 | FOLH1 (0.55) | FOLH1GNPATSMN1; SMN2KDM4EMAPT | |
| SCHEMBL22769501 | 0.95 | FOLH1 (0.55) | FOLH1GNPATSMN1; SMN2KDM4EMAPT | |
| SCHEMBL29550463 | 0.95 | FOLH1 (0.55) | FOLH1GNPATSMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011156-A | Weight-losing peptide with high activity and preparation method and application thereof | 济南健丰化工有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4731755-A2 | COMPOSITIONS AND METHODS FOR REDUCING HOST CELL PROTEINS IN RECOMBINANT ADENO-ASSOCIATED VIRUS PREPARATIONS | Ultragenyx Pharmaceutical Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-12599669-B2 | Use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations | AMGEN INC. (US) | 2026-04-14 | — | — | US | claimed |
| US-20260049105-A1 | SELECTIVE MC4R LIGAND FOR TREATING OBESITY AND COGNITIVE LOSS | UNIV ARIZONA (US) | 2026-02-19 | — | — | US | claimed |
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | AMGEN INC. (US) | 2025-12-04 | — | — | US | claimed |
| WO-2025245279-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245258-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONIST ANALOGS FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245294-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245244-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONIST ANALOGS FOR MODULATING WEIGHT LOSS | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245252-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONIST ANALOGS FOR USE IN PAIN MANAGEMENT AND/OR SUBSTANCE USE DISORDERS | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2000040217-B1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-10-05 | — | — | WO | claimed |
| EP-0754023-B1 | INHIBITION OF HAIR GROWTH | HANDELMAN JOSEPH H (US) | 1999-05-26 | — | — | EP | claimed |
| EP-0673432-B1 | PROCESS FOR PREPARING CLAVULANIC ACID | SMITHKLINE BEECHAM PLC (GB) | 1999-03-24 | — | — | EP | claimed |
| US-5869299-A | USING AN ENZYME SYSTEM FROM STREPTOMYCES, PARTICULARLY S. CLAVULIGERUS. | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-02-09 | — | — | US | claimed |
| US-5686416-A | BRADYKININ ANALOGUES; NONA-, DECA- AND POLYPEPTIDES | ALKERMES, INC. (US) | 1997-11-11 | — | — | US | claimed |
| EP-0736770-A2 | An immunoreactive conjugate, method for its preparation, antibodies to said conjugate and a pharmaceutical composition and diagnostic device containing them | ANDA BIOLOGICALS S.A. (FR) | 1996-10-09 | — | — | EP | claimed |
| US-5468476-A | Enzyme inhibitor | GILLETTE CO., THE | 1995-11-21 | — | — | US | claimed |
| EP-0673432-A1 | PROCESS FOR PREPARING CLAVULANIC ACID | SMITHKLINE BEECHAM PLC (GB) | 1995-09-27 | — | — | EP | claimed |
| US-5350766-A | Method for the prevention and/or palliation of the complications of diabetes using N-alpha orginine acetyl | NEW YORK MEDICAL COLLEGE (US) | 1994-09-27 | — | — | US | claimed |
| WO-1994012654-A1 | PROCESS FOR PREPARING CLAVULANIC ACID | SMITHKLINE BEECHAM PLC (GB) | 1994-06-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049105-A1 | SELECTIVE MC4R LIGAND FOR TREATING OBESITY AND COGNITIVE LOSS | MC4R, MC3R, NPY4R | FOLH1 2873/4885GNPAT 2101/4885SMN1; SMN2 3094/4885 |
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | ARGLU1, ARG1, FCGRT | FOLH1 405/4885GNPAT 4113/4885SMN1; SMN2 3271/4885 |
| US-12599669-B2 | Use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations | PNISR, ALB, ACP1 | FOLH1 2031/4885GNPAT 3020/4885SMN1; SMN2 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.